Related Experiment Video
Updated: Jun 1, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Anidulafungin: when and how? The clinician's view
Jomy George1, Annette C Reboli
1Department of Pharmacy Practice and Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA. j.george@usp.edu
Abstract:
Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.
Insights
Anidulafungin is a new antifungal drug effective against Candida species, including resistant strains. It shows good tolerability and efficacy in treating candidiasis without significant drug interactions or dosage adjustments.
Area of Science:
- Pharmacology
- Infectious Diseases
- Mycology
Background:
- Anidulafungin represents a novel echinocandin antifungal agent.
- It targets the fungal cell wall synthesis pathway.
- Addresses the need for new treatments against resistant fungal infections.
Purpose of the Study:
- To review the profile of Anidulafungin.
- To highlight its efficacy and safety in treating fungal infections.
- To discuss its unique pharmacokinetic and pharmacodynamic properties.
Main Methods:
- Clinical trial data review.
- Pharmacological studies analysis.
- Efficacy and safety assessments.
Main Results:
- Anidulafungin exhibits fungicidal activity against Candida species, including azole and polyene-resistant isolates.
- It demonstrates fungistatic activity against Aspergillus species.
- No clinically significant drug interactions were observed, and no dosage adjustments are needed for renal or hepatic impairment.
- Anidulafungin was well-tolerated in clinical trials.
Conclusions:
- Anidulafungin is a well-tolerated and effective option for candidiasis treatment.
- Its favorable drug interaction profile and lack of need for dosage adjustments in organ impairment make it a valuable therapeutic choice.
- Anidulafungin expands treatment options for invasive fungal infections.
Related Concept Videos
Antifungal Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Anthelminthic Agents
Candidiasis
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Fungal Phylum Microsporidia
